Smart drugs: Tyrosine kinase inhibitors in cancer therapy. Cancer Cell 2002; 1: 117- 23.Shawver LK, Slamon D, Ullrich A. Smart drugs: tyrosine kinase inhibitors in cancer therapy. Cancer Cell. 2002;1:117-23.Shawver, L.K., Slamon, D., and Ullrich, A. (2002). Smart drugs: tyrosine ...
TYROSINE KINASE TARGETING DRUGS-ASSOCIATED CONGESTIVE HEART FAILURE: TRASTUZUMAB, CETUXIMAB, PANITUMUMAB AND SUNITINIB ARE ASSOCIATED WITH INCREASED RISK.BarnettCarmelO.CarmelRennertCarmelG.CarmelLaviCarmelI.CarmelAbernethyCarmelD.CarmelR.CarmelGronich
different humanmalignancies. Moreover, PTKs are considered therapeutic targets in cancer [54,55]. AlthoughTyrosine kinase inhibitors(TKIs) therapy has led to increasing lifespans for many patients with blood and solid cancers, drug resistance andcancer relapsecontinue to be a major limit. Autophagic ...
Protein kinase inhibitors: the tyrosine specific protein kinases. Pharmacol Ther 1998; 77(2): 81–114 PubMed CAS Google Scholar Shawver L. Tyrosine kinase inhibitors: from the emergence of targets to their clinical development. In: Perry MC, editor. American Society of Clinical Oncology ...
FULL PAPER British Journal of Cancer (2017) 116, 1366–1373 | doi: 10.1038/bjc.2017.88 Keywords: heart failure; tyrosine kinase-targeting drugs; cardio-oncology; adverse effects Tyrosine kinase-targeting drugs-associated heart failure N Gronich*,1, I Lavi1, O Barnett-Griness1, W Saliba1, D...
Proposed cellular mechanisms ofon- and off-targeteffects of multi-kinase inhibitors. Off-target toxic effects are a result of the inhibition of kinases other than the intended target of the TKIs. Off-target blockage of AMPK by drugs like sunitinib leads to superoxide production in mitochondria res...
“With second-generation tyrosine kinase inhibitors, you get deeper responses, you get faster responses; you actually get more responses and a lower rate of transformation,” he indicated. “They don’t give you a survival advantageor at least they haven’t so ...
Bruton’s tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic signaling that is critical for proliferation and survival of leukemic cells in many B cell malignancies. BTK was initially shown to be defective in the primar
cells is severely impaired [7,8,9,10]. Importantly, BTK has received large interest since small-molecule inhibitors of this kinase have shown excellent anti-tumor activity in clinical studies [11,12]. In particular, the orally administered BTK inhibitor ibrutinib, which forms a covalent bond ...
Since the discovery that non-small cell lung cancer (NSCLC) is driven by epidermal growth factor receptor (EGFR) mutations, the EGFR tyrosine kinase inhibitors (EGFR-TKIs, e.g., gefitinib and elrotinib) have been effectively used for clinical treatment. However, patients eventually develop drug...